Thermo Fisher Scientific (NYSE:TMO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Thermo Fisher Scientific (NYSE:TMO) from a hold rating to a buy rating in a research note issued to investors on Saturday.

Several other brokerages have also issued reports on TMO. KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Robert W. Baird lowered their price objective on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Weiss Ratings upgraded Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. Jefferies Financial Group reiterated a “buy” rating and issued a $630.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. Finally, Stifel Nicolaus dropped their price objective on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a research note on Friday, April 24th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $617.14.

Thermo Fisher Scientific Trading Down 0.0%

Shares of NYSE:TMO opened at $574.29 on Friday. The company has a market cap of $213.42 billion, a PE ratio of 30.89, a P/E/G ratio of 2.34 and a beta of 0.87. The company’s 50 day moving average is $509.02 and its two-hundred day moving average is $511.04. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific has a 52 week low of $435.27 and a 52 week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. During the same period last year, the firm earned $4.28 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities analysts predict that Thermo Fisher Scientific will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is 10.11%.

Insider Activity

In related news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $565.00, for a total value of $226,000.00. Following the sale, the chief operating officer directly owned 24,651 shares of the company’s stock, valued at approximately $13,927,815. This trade represents a 1.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.33% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. High Note Wealth LLC lifted its holdings in shares of Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 29 shares in the last quarter. Swiss RE Ltd. bought a new position in Thermo Fisher Scientific during the 4th quarter valued at $28,000. Legacy Wealth Managment LLC ID increased its holdings in Thermo Fisher Scientific by 78.6% in the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after buying an additional 22 shares during the last quarter. Birchwood Financial Partners Inc. bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $29,000. Finally, Core Wealth Advisors LLC bought a new stake in Thermo Fisher Scientific during the fourth quarter valued at $30,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.